[go: up one dir, main page]

PE8798A1 - Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil] - Google Patents

Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]

Info

Publication number
PE8798A1
PE8798A1 PE1996000507A PE00050796A PE8798A1 PE 8798 A1 PE8798 A1 PE 8798A1 PE 1996000507 A PE1996000507 A PE 1996000507A PE 00050796 A PE00050796 A PE 00050796A PE 8798 A1 PE8798 A1 PE 8798A1
Authority
PE
Peru
Prior art keywords
methyl
enantiomers
azabiciclo
metoxy
octan
Prior art date
Application number
PE1996000507A
Other languages
English (en)
Inventor
Derek L Tickner
Morgan Meltz
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE8798A1 publication Critical patent/PE8798A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

CARACTERIZADO PORQUE COMPRENDE: 1) HACER REACCIONAR EL RACEMATO CON EL ACIDO 1R-(-)-10-CANFORSULFONICO, EN PRESENCIA DE UN DISOLVENTE TAL COMO ACETONITRILO, ACETONA O ETANOL, HACIENDO POSIBLE DISOLVER EN FORMA SELECTIVA EL ENANTIOMERO (2S,3S) DEL ENANTIOMERO (2R,3R), DONDE TALES ENANTIOMEROS SE ENCUENTRAN EN FORMA DE SAL CANFORSULFONICO; 2) HIDROLIZAR LA SAL QUE PRECIPITA EN SOLUCION, PARA OBTENER LA BASE LIBRE DEL ENANTIOMERO (2S,3S). ES ANTAGONISTA DEL RECEPTOR DE LA SUSTANCIA P, SIENDO USADO EN EL TRATAMIENTO Y LA PREVENCION DE UNA AMPLIA GAMA DE TRANSTORNOS DEL SISTEMA NERVIOSO CENTRAL, GASTROINTESTINALES, ENTRE OTROS
PE1996000507A 1995-07-17 1996-07-03 Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil] PE8798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US119195P 1995-07-17 1995-07-17

Publications (1)

Publication Number Publication Date
PE8798A1 true PE8798A1 (es) 1998-03-02

Family

ID=21694832

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000507A PE8798A1 (es) 1995-07-17 1996-07-03 Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]

Country Status (25)

Country Link
US (1) US6008357A (es)
EP (1) EP0840735B1 (es)
JP (1) JP3043074B2 (es)
KR (1) KR100276989B1 (es)
CN (1) CN1068598C (es)
AR (1) AR002772A1 (es)
AT (1) ATE250600T1 (es)
AU (1) AU697553B2 (es)
CA (1) CA2227194C (es)
CO (1) CO4480720A1 (es)
CZ (1) CZ15098A3 (es)
DE (1) DE69630123T2 (es)
DK (1) DK0840735T3 (es)
ES (1) ES2205039T3 (es)
HU (1) HUP9900238A3 (es)
IL (1) IL122655A0 (es)
MY (1) MY115734A (es)
NO (1) NO980211L (es)
NZ (1) NZ310539A (es)
PE (1) PE8798A1 (es)
PL (1) PL184261B1 (es)
PT (1) PT840735E (es)
RU (1) RU2136681C1 (es)
WO (1) WO1997003984A1 (es)
ZA (1) ZA966026B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05516B1 (et) * 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
BRPI0507334A (pt) * 2004-02-02 2007-07-03 Pfizer Prod Inc processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina
EP1812391A2 (en) * 2004-11-10 2007-08-01 Boehringer Ingelheim Chemicals, Inc. Process of making fentanyl intermediates
CA2746422A1 (en) * 2008-12-09 2010-06-17 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
NO168529C (no) * 1989-09-15 1992-03-04 Chiron Lab As Fremgangsmaate for fremstilling av s-(-) og r-(+)-n-(quinuclidinyl-3)-amider.
FI935134L (fi) * 1991-05-22 1993-11-19 Pfizer Substituerade 3-aminokinuklidiner
DE9290063U1 (de) * 1991-05-31 1994-02-24 Pfizer Inc., New York, N.Y. Chinuclidin-Derivate
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists

Also Published As

Publication number Publication date
JPH10511102A (ja) 1998-10-27
AU6134896A (en) 1997-02-18
DK0840735T3 (da) 2004-02-09
DE69630123T2 (de) 2004-04-08
CN1190970A (zh) 1998-08-19
PL324610A1 (en) 1998-06-08
CA2227194C (en) 2002-02-12
MX9800538A (es) 1998-05-31
US6008357A (en) 1999-12-28
HUP9900238A3 (en) 2001-08-28
ATE250600T1 (de) 2003-10-15
AR002772A1 (es) 1998-04-29
ES2205039T3 (es) 2004-05-01
HUP9900238A2 (hu) 1999-05-28
DE69630123D1 (en) 2003-10-30
AU697553B2 (en) 1998-10-08
NO980211D0 (no) 1998-01-16
EP0840735A1 (en) 1998-05-13
MY115734A (en) 2003-08-30
CZ15098A3 (cs) 1999-02-17
HK1010195A1 (en) 1999-06-17
NO980211L (no) 1998-03-16
PL184261B1 (pl) 2002-09-30
RU2136681C1 (ru) 1999-09-10
EP0840735B1 (en) 2003-09-24
WO1997003984A1 (en) 1997-02-06
JP3043074B2 (ja) 2000-05-22
KR19990029058A (ko) 1999-04-15
PT840735E (pt) 2004-02-27
NZ310539A (en) 1998-11-25
CN1068598C (zh) 2001-07-18
ZA966026B (en) 1998-01-16
IL122655A0 (en) 1998-08-16
CO4480720A1 (es) 1997-07-09
CA2227194A1 (en) 1997-02-06
KR100276989B1 (ko) 2001-01-15

Similar Documents

Publication Publication Date Title
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
ES2013129A6 (es) Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
FR2430403A1 (fr) Nouvelles 15-deoxy-16-hydroxy-prostaglandines, leur procede de production et medicament les contenant
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
CO4920242A1 (es) Compuestos inhibidores de metalopreoteasas 1,4-heterocicli- cos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
DE122005000045I1 (de) R-Enantiomer von N-Propargyl-1-aminoindan, dessen Herstellung und dieses enthaltende pharmazeutischeZusammensetzungen.
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
CO4900036A1 (es) Compuestos inhibidores de metaloproteasas de amina ciclica substituida composiciones farmaceuticas que los contienen y metodos para su utilizacion
MX9100160A (es) Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
CO4900045A1 (es) Compuestos inhibidores de metaloproteasas espirociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
PE20050011A1 (es) Compuesto de difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion y medicamentos que comprenden este compuesto
PE8798A1 (es) Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
EE05085B1 (et) Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
PT97300A (pt) Processo para a preparacao de esteres de acidos 1,4-di-hidropiridinocarboxilicos n-alquilados e de medicamentos que os contem
PT1194415E (pt) Novos derivados da piperazinil-alquil-tiopirimidina composicoes farmaceuticas que os contem e um processo de preparacao da substancia activa
ES2075860T3 (es) Sales de 4-hidroxi-8-(3-alcoxi c1-6-4-fenilsulfinilfenil)pirazolo(1,5-a)-1,3,5-triazinas opticamente activas y procedimiento para su produccion.
AR027578A1 (es) Derivados de indano
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
PE20021016A1 (es) Conjugados de pregabalina-lactosa
EA199800155A1 (ru) Новое соединение
EA200000322A1 (ru) Способ синтеза производных хинолина

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed